DOP076 A phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinab, an oral JAK inhibitor, in patients with moderately to severely active ulcerative colitis
Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Colleen Marano(Johnson & Johnson (United States)), Zijiang Yang(Henan Medical University), Julián Panés(Hospital Clínic de Barcelona), H. Zhang(Janssen (United States)), Brian G. Feagan(Western University), W. Sandborn, Philippe Szapary(Cedars-Sinai Medical Center), Gary R. Lichtenstein(University of Pennsylvania), Chris O’Brien(Neurocrine Biosciences (United States)), Jewel Johanns(Johnson & Johnson (United States)), Richard Strauß(Hennepin County Medical Center), Jesse Dewey(Janssen (United States)), Séverine Vermeire(KU Leuven)
Cited by 1
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k